Check the dosage of Evusheld™ when comparing to existing code Q0220. Medicare announced a new HCPCS Level II code for tixagevimab co-packaged with cilgavimab (EVUSHELD™), which providers administer as a preventive medicine for certain patients before exposure to COVID-19. The effective date of Q0221 is Feb. 24, 2022. Compare Q0221 to Q0220 Note the 600 […]
The post Add Q0221 for COVID-19 Preventive Drug appeared first on AAPC Knowledge Center.